Flebogamma
Flebogamma is a sterile, highly purified preparation of human normal immunoglobulin G (IgG) obtained from plasma donor pools. It provides passive immunization by increasing abnormally low immunoglobulin G levels to normal ranges.
Dosage by Body Weight
Dosage must be individualized and calculated based on clinical indication, patient body weight, and response to therapy. It is administered strictly via intravenous infusion in a clinical setting under professional supervision.
- Body Weight
- Below 5 kg
- Dose
- 1.0 g to 4.0 g (calculated at 0.2 to 0.8 g/kg for replacement therapy)
- Frequency
- Every 3 to 4 weeks (Replacement)
- Tracking Notes
- Initiate at a very slow infusion rate. Monitor vital signs continuously.
- Body Weight
- 5-7 kg
- Dose
- 1.0 g to 5.6 g (calculated at 0.2 to 0.8 g/kg for replacement therapy)
- Frequency
- Every 3 to 4 weeks (Replacement)
- Tracking Notes
- Immunomodulatory doses are higher (typically 1 to 2 g/kg) and may be split over several days.
- Body Weight
- 8-10 kg
- Dose
- 1.6 g to 8.0 g (calculated at 0.2 to 0.8 g/kg for replacement therapy)
- Frequency
- Every 3 to 4 weeks (Replacement)
- Tracking Notes
- Ensure adequate hydration prior to starting the infusion to reduce the risk of renal complications.
- Body Weight
- 11-15 kg
- Dose
- 2.2 g to 12.0 g (calculated at 0.2 to 0.8 g/kg for replacement therapy)
- Frequency
- Every 3 to 4 weeks (Replacement)
- Tracking Notes
- Gradually increase infusion rate only if the patient tolerates the initial rate well.
- Body Weight
- 16-20 kg
- Dose
- 3.2 g to 16.0 g (calculated at 0.2 to 0.8 g/kg for replacement therapy)
- Frequency
- Every 3 to 4 weeks (Replacement)
- Tracking Notes
- Dosing intervals may be adjusted based on clinical response and serum IgG trough levels.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | 1.0 g to 4.0 g (calculated at 0.2 to 0.8 g/kg for replacement therapy) | Every 3 to 4 weeks (Replacement) | Initiate at a very slow infusion rate. Monitor vital signs continuously. |
| 5-7 kg | 1.0 g to 5.6 g (calculated at 0.2 to 0.8 g/kg for replacement therapy) | Every 3 to 4 weeks (Replacement) | Immunomodulatory doses are higher (typically 1 to 2 g/kg) and may be split over several days. |
| 8-10 kg | 1.6 g to 8.0 g (calculated at 0.2 to 0.8 g/kg for replacement therapy) | Every 3 to 4 weeks (Replacement) | Ensure adequate hydration prior to starting the infusion to reduce the risk of renal complications. |
| 11-15 kg | 2.2 g to 12.0 g (calculated at 0.2 to 0.8 g/kg for replacement therapy) | Every 3 to 4 weeks (Replacement) | Gradually increase infusion rate only if the patient tolerates the initial rate well. |
| 16-20 kg | 3.2 g to 16.0 g (calculated at 0.2 to 0.8 g/kg for replacement therapy) | Every 3 to 4 weeks (Replacement) | Dosing intervals may be adjusted based on clinical response and serum IgG trough levels. |
Formulation
Purpose
Used for replacement therapy in primary and secondary immunodeficiency syndromes, and for immunomodulation in autoimmune diseases like primary immune thrombocytopenia, Guillain-Barré syndrome, Kawasaki disease, and chronic inflammatory demyelinating polyneuropathy.
Generic Name
Human Normal Immunoglobulin (IVIG)Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.